Brown Miller Wealth Management LLC Boosts Position in Zoetis Inc. $ZTS

Brown Miller Wealth Management LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 2.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,299 shares of the company’s stock after purchasing an additional 178 shares during the period. Brown Miller Wealth Management LLC’s holdings in Zoetis were worth $1,450,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ZTS. Sound Income Strategies LLC boosted its stake in Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after acquiring an additional 152 shares in the last quarter. Portside Wealth Group LLC boosted its position in shares of Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock valued at $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. grew its stake in Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after buying an additional 198,089 shares during the last quarter. Soros Capital Management LLC increased its position in Zoetis by 32.0% during the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock worth $2,872,000 after buying an additional 4,230 shares during the period. Finally, Flagship Harbor Advisors LLC lifted its stake in Zoetis by 31.2% in the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock valued at $1,217,000 after buying an additional 1,760 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.0%

Shares of NYSE:ZTS opened at $146.45 on Friday. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm’s 50-day simple moving average is $149.79 and its 200-day simple moving average is $155.08. The company has a market cap of $64.91 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the firm earned $1.56 earnings per share. The firm’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ZTS shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Saturday, September 27th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and reduced their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Argus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Moderate Buy” and an average price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.